BioSpace News Archive

Olink Holding AB announced it will release financial results for the second quarter of 2023 before the market open on Wednesday, August 9, 2023.

Recce Pharmaceuticals Ltd is pleased to announce it received further non-dilutive funds from Radium Capital for A$801,604 of Recce’s future R&D tax incentive.

Alignment Healthcare, Inc. (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, will release its second quarter 2023 financial results on Thursday, Aug. 3, after market close.

Incannex Healthcare Limited is pleased to announce that it has received approval from Bellberry Human Research Ethics Committee (‘HREC’) for the lead site, Emeritus Research, Camberwell, Victoria, for its Phase 2 clinical trial.

SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today that it has acquired two life-saving medicines, Vistogard ® (uridine triacetate) and Xuriden ® (uridine triacetate), from Wellstat Therapeutics.

Health Canada has granted a Notice of Compliance with Conditions (NOC/c) for Lynparza® (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA.

MEI Pharma, Inc. announced that it has postponed its special meeting in connection with the proposed transaction with Infinity Pharmaceuticals, Inc. to July 23, 2023, at 10:00 a.m. Eastern Time, unless postponed or adjourned to a later date.

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American rights to the drug as well as global rights in Rett syndrome and Fragile X syndrome to Neuren’s development candidate NNZ-2591.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to two new employees.

Petros Pharmaceuticals, Inc. announces a $15 million private placement financing that will support its continued progress towards bringing its erectile dysfunction drug, STENDRA, to non-prescription OTC status.